PENG Block in Comparison With FICB for Hip Reconstruction in Children
Launched by SAINT PETERSBURG STATE UNIVERSITY, RUSSIA · Jan 14, 2024
Trial Information
Current as of July 09, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating two different ways to manage pain for children undergoing hip reconstruction surgery, particularly those with conditions like cerebral palsy and spina bifida. The researchers want to see if a method called the Pericapsular nerve group (PENG) block provides better pain relief during and after surgery compared to another method known as the Fascia iliaca compartment block (FICB).
To be eligible for this study, children ages 3 to 18 who are scheduled for hip joint surgery and have either cerebral palsy or spina bifida may participate. However, children who cannot safely receive local anesthetics or who have certain health issues may not be able to join. Participants will receive either of the pain management techniques and will be monitored for their pain levels and recovery. This study is currently looking for volunteers, and it aims to help improve pain control for children undergoing these types of surgeries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • reconstructive surgery on the hip joint
- • children with cerebral palsy/ spina bifida/organic brain injury
- • age 3 - 18 years.
- Exclusion Criteria:
- • contraindications to the use of local anesthetics
- • contraindications to performing an invasive procedure
- • ASA \> 3
About Saint Petersburg State University, Russia
Saint Petersburg State University, established in 1724, is a prestigious institution in Russia known for its commitment to academic excellence and research innovation. As a clinical trial sponsor, the university leverages its extensive resources and expertise to advance medical knowledge and improve patient outcomes through rigorous scientific investigation. With a focus on multidisciplinary collaboration, the university fosters partnerships with healthcare professionals, researchers, and industry stakeholders to conduct high-quality clinical trials that adhere to international standards. Its mission is to contribute to the global healthcare landscape by generating reliable data that informs clinical practices and therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint Petersburg, , Russian Federation
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported